In the Specification:

The paragraph beginning on page 9, line 24 of the substitute specification filed 12/07/2004 is amended as follows:

Figure 1A-H: Examples of Nicotinic acid derivatives ~~**to be conjugated with the different polymers as shown in Figures 2-4.**~~ The compositions of the present invention may include the nicotinic acid derivatives in Figures 1A-H alone or as conjugated with different polymers as shown, for example, in Figures 2-4.

In the Claims:

Please amend claim 31. Please add new claim 64. The claims are as follows:

1-30. (Canceled)

31. (Currently amended) A pharmaceutical composition, said composition comprising:

a nicotine structure consisting of nicotine or a polymeric form thereof; and

a nicotinic acid analog structure ~~consisting of nicotinic acid analogs or a polymeric form thereof~~ comprising a nicotinic acid derivative, wherein the nicotinic acid analog structure in the composition is in an amount effective for promoting angiogenesis in a subject as a result of administering the composition to the subject, and wherein the nicotinic acid analog structure in the composition is configured to promote said angiogenesis in the subject independent of the nicotine structure in the composition.

32. (Previously presented) The composition of claim 31, wherein the nicotinic acid analog structure is conjugated to a member selected from the group consisting of polyvinyl alcohol, acrylic acid ethylene co-polymer, polyethyleneglycol (PEG), and polylactic acid.

33. (Previously presented) The composition of claim 32, wherein the nicotinic acid analog structure is conjugated to the member via a covalent bond.

34. (Previously presented) The composition of claim 33, wherein the covalent bond is an ester linkage or an anhydride linkage.

35. (Withdrawn) The composition of claim 32, wherein the nicotinic acid analog structure is conjugated to the member via a non-covalent bond.

36. (Withdrawn) The composition of claim 31, wherein the nicotinic acid analog structure is encapsulated or incorporated in a microparticle or liposome.

37. (Withdrawn) The composition of claim 36, wherein the microparticle or liposome has a size less than 200 nanometers.

38. (Withdrawn) The composition of claim 31, wherein the nicotinic acid analog structure is encapsulated or incorporated in a polymer.

39. (Previously presented) The composition of claim 31, wherein the composition further comprises at least one substance selected from the group consisting of a growth factor, a vasodilator, an anticoagulant, and combinations thereof.

40. (Previously presented) The composition of claim 39, wherein the at least one substance comprises the growth factor.

41. (Previously presented) The composition of claim 40, wherein the growth factor is a fibroblast growth factor (FGF2) or a vascular endothelial growth factor (VEGF).

42. (Withdrawn) The composition of claim 39, wherein the at least one substance comprises the vasodilator.

43. (Withdrawn) The composition of claim 42, wherein the vasodilator is selected from the group consisting of nitric oxide donors, adenosine analogs, phosphodiaesterase inhibitors, and apomorphine.

44. (Withdrawn) The composition of claim 39, wherein the at least one substance comprises the anticoagulant.

45. (Withdrawn) The composition of claim 44, wherein the anticoagulant is selected from the group consisting of heparin, heparin derivatives, anti-factor Xa, anti-thrombin, aspirin, clopidgrel, and combinations thereof.

46. (Withdrawn) The composition of claim 39, wherein the at least one substance comprises the growth factor and the vasodilator.

47. (Withdrawn) The composition of claim 39, wherein the at least one substance comprises the growth factor and the anticoagulant.

48. (Withdrawn) The composition of claim 39, wherein the at least one substance comprises the vasodilator and the anticoagulant.

49. (Withdrawn) The composition of claim 39, wherein the at least one substance comprises the growth factor, the vasodilator, and the anticoagulant.

50. (Withdrawn) A method of treating a disease in a patient via promotion of angiogenesis in the patient, said method comprising administering the composition of claim 1 to the patient to promote angiogenesis in the patient, wherein the subject is the patient.

51. (Withdrawn) The method of claim 50, wherein the disease or disorder is selected from the group consisting of occlusive vascular disease, coronary disease, erectile dysfunction, myocardial infarction, ischemia, stroke, peripheral artery vascular disorders, wounds, and combinations thereof.

52. (Withdrawn) The method of claim 51, wherein the disease or disorder comprises said occlusive vascular disease or disorder.

53. (Withdrawn) The method of claim 52, wherein the occlusive vascular disease or disorder comprises a venous disease or disorder.

54. (Withdrawn) The method of claim 53, wherein the venous disease or disorder is selected from the group consisting of deep vein thrombosis, sickle cell disease, and pulmonary embolism.

55. (Withdrawn) The method of claim 52, wherein the occlusive vascular disease or disorder comprises an arterial disease or disorder.

56. (Withdrawn) The method of claim 55, wherein the arterial disease or disorder comprises an arterial thromboembolic disease or disorder selected from the group consisting of coronary artery diseases, cerebrovascular disorders, and peripheral artery diseases.

57. (Withdrawn) The method of claim 50, wherein a medical device is coated with the composition, and wherein said administering comprises inserting the medical device into the patient.

58. (Withdrawn) The method of claim 57, wherein the medical device is a stent, a catheter, a carmula, or an electrode.

59. (Withdrawn) The method of claim 50, wherein the subject is selected from the group consisting of a human being, a cow, sheep, a horse, a pig, cattle, a goat, a dog, a mouse, a mouse, a rat, a cultured cell, and transgenic species thereof.

60. (Withdrawn) The method of claim 50, wherein the subject is a human being.

61. (Previously presented) The composition of claim 41, wherein the growth factor comprises the vascular endothelial growth factor (VEGF).

62. (Withdrawn) The composition of claim 43, wherein the vasodilator comprises the phosphodiaesterase inhibitors.

63. (Withdrawn) The composition of claim 45, wherein the anticoagulant comprises the heparin derivatives.

64. (New) The composition of claim 31, wherein the nicotinic acid analog structure is conjugated to a member selected from the group consisting of polyvinyl alcohol, acrylic acid ethylene co-polymer, and polylactic acid.